Alvogen Continues IP Fight Over Cancer Drug Imbruvica
In a rematch over the leukemia medication Imbruvica, AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech urged the Federal Circuit Friday to uphold a lower court ruling that their four...To view the full article, register now.
Already a subscriber? Click here to view full article